- Investing.com
Lonza Group AG (Lonza) is a Switzerland-based holding company and a supplier to the pharmaceutical, healthcare and life science industries. The Company's offerings include custom development and manufacturing of drugs and drug delivery systems, as well as development of anti-microbial solutions for commercial applications. The Company divides its activities into two segments: Pharma&Biotech and Specialty Ingredients. The Pharma&Biotech comprises the Company's Biologics, Small-Molecule, and Consumables and Research Tools businesses. The segment includes mammalian, microbial, chemical, bioconjugates, cell and gene therapy technology platforms. The Specialty Ingredients segment focuses on anti-microbial applications within Consumer Health division, which covers hygiene, nutrition and personal care products, as well as preservatives, capsules and food supplements, among others, and Consumer & Resources Protection division, which includes coatings and composites, and agro ingredients.
Metrics to compare | LONN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLONNPeersSector | |
---|---|---|---|---|
P/E Ratio | 66.2x | 24.4x | −0.6x | |
PEG Ratio | −1.37 | −0.06 | 0.00 | |
Price/Book | 4.1x | 2.7x | 2.6x | |
Price / LTM Sales | 5.7x | 4.2x | 3.2x | |
Upside (Analyst Target) | 20.0% | 15.8% | 41.1% | |
Fair Value Upside | Unlock | 8.7% | 5.9% | Unlock |